A randomized, double-blind, placebo-controlled, phase III study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting.
Cancer Clinical Trials
Breast - Advanced ER (+) HER2 (-)
Monarch 3 (I3Y-MC-JPBM)
Breast - Metastatic, BRCA 1 and BRCA 2
Brocade 3 (M12-914)
A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.
Breast - Operable, HER2 (+)
A randomized, multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
ASBrS Nipple Sparing Mastectomy Registry.
Breast – Advanced ER (+) HER2 (-)
MONARCH 2 (I3Y-MC-JPBL)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer.
A randomized, phase II, multicenter placebo-controlled study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer.
Gastric – Metastatic
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-line Therapy in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
City of Hope Registry
Molecular Genetics Studies of Cancer Patients and Their Relatives
Head and Neck – Recurrent or Metastatic
A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Lung - Metastatic
Randomized, double blind, multicenter, phase III study comparing veliparib (ABT-888) plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in previously untreated advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Lung – Early Stage
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI−PD-L1 Antibody) Compared with best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer.
Lung – Metastatic
A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti−Pd-L1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer.
Lung – NSCLC (Treatment Experienced)
JAVELIN (EMR 100070-004)
A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects with Non-Small Cell Lung Cancer that has Progressed After a Platinum-Containing Doublet.
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.
Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)
Connect® MDS and AML Registry
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.